6H-BENZOFURO(3A,3,2-EF)(2)BENZAZEPIN-6-OL, 4A,5,9,10,11,12-HEXAHYDRO-3-METHOXY-11-METHYL-, (4AS,6R,8AS)
Traumatic Brain Injury
INTRuST, Post-Traumatic Stress Disorder - Traumatic Brain Injury Clinical ConsortiumSmall moleculePhase 4 / ApprovedDormant
BB
68/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 53/ 100
- Competitive Position
- 95/ 100
Competitive context
83 Active assets in the Traumatic Brain Injury cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Melatonin Children's National Research Institute | Phase 4 | BBB |
Valproic Acid Northwestern University | Phase 4 | BBB |
Apsolol Tanta University | Phase 4 | BBB |
Nepenthe Henry M. Jackson Foundation for the Advancement of Military Medicine | Phase 4 | BB |
Amantadine SHINKEI Therapeutics, Inc | Phase 4 | BB |
View all 50 →
Same molecule, other indications
6H-BENZOFURO(3A,3,2-EF)(2)BENZAZEPIN-6-OL, 4A,5,9,10,11,12-HEXAHYDRO-3-METHOXY-11-METHYL-, (4AS,6R,8AS) is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →